logo-loader
Q BioMed Inc

Full interview: Q BioMed successfully synthesizes molecule to treat liver cancer in a 'tremendously exciting achievement'

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive that the New York-based biotech, together with India-based research organization Chemveda Life Sciences, has made a breakthrough with its therapy as a potential chemotherapy to treat liver cancer.

Corin says the molecule called Uttroside-B, is in pre-clinical development, and the company looks forward to submit it as an investigational new drug in 1Q of 2020.

Quick facts: Q BioMed Inc

Price: $0.76

Market: OTCQB
Market Cap: $11.15 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc named herein, including the promotion by the Company of Q BioMed Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

More on this story

Watch

Full interview: hVIVO PLC's 2020 pipeline 'looking strong' as it expands...

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

7 hours, 27 minutes ago

2 min read